Recent business developments primarily relate to Tharimmune, a related entity, including executive appointments and operational approvals on the Canton Network.

• Tharimmune appointed Radkowski as COO and named CEO Wendland as Chairman in February 2026 [N1].
• Tharimmune gained approval to run a Super Validator on the Canton Network in January 2026 [N2].
• Tharimmune named Jacob Asbury as CFO in December 2025 [N3].
• Insider purchases of Tharimmune shares were reported in June 2025 by the Executive Chairman and a Director [N4][N5].
• Rodman & Renshaw initiated coverage of Tharimmune with a Buy recommendation in December 2024 [N6][N7].
• Tharimmune presented clinical data on TH104 for chronic pruritus in November 2024 [N8].

The company’s strategic pivot to digital asset treasury management positions it to capitalize on the growth and adoption of the Canton Network, which processes significant volumes of tokenized real-world assets. Its role as a Super Validator and active governance participation may provide recurring protocol rewards and influence over network development. The diversified approach to token management, including locking, lending, and options, could enhance capital efficiency and yield generation. Strategic investments in complementary applications and middleware may expand network utilization and institutional adoption, potentially increasing long-term network value.

The shift from biotechnology to a digital asset treasury strategy introduces significant execution and market risks, including potential loss of revenue streams from prior operations and residual liabilities. Regulatory developments related to crypto assets and digital tokens like CC remain uncertain and could impose restrictions or adversely affect token value and liquidity. Market volatility and liquidity constraints in CC holdings may cause substantial financial fluctuations. Dependence on third-party custodians and service providers introduces operational and cybersecurity risks. The company’s limited operating history in its new business model and concentrated exposure to CC heighten uncertainty regarding future performance and profitability.

Canton Strategic Holdings’ moat derives from its unique position as the first publicly traded company focused on leveraging Canton Coin and the Canton Network, a blockchain designed for institutional privacy and interoperability. Its role as a Super Validator and active participation in the Canton Foundation’s governance provide strategic influence and alignment with the network’s development. The company’s diversified digital asset treasury strategy, including validator operations, strategic investments, and token management, supports capital efficiency and ecosystem engagement. The proprietary technology of the Canton Network, combined with its institutional adoption and differentiated tokenomics, creates barriers to entry for competitors. However, the company’s moat is moderated by regulatory uncertainties and the evolving nature of digital asset markets.

• Strategic Shift Risks: The transition from biotechnology to a digital asset treasury strategy changes the company’s risk profile, potentially reducing focus on prior revenue streams and exposing it to legacy liabilities.
• Regulatory Risks: Uncertain and evolving regulations around digital assets and crypto tokens like CC could impose new compliance burdens, restrict operations, or affect token valuation.
• Market and Liquidity Risks: CC token holdings are subject to significant price volatility, limited liquidity, and market disruptions, which may impact financial results and stock price.
• Operational and Custody Risks: Reliance on third-party custodians and infrastructure providers exposes the company to risks of service failures, cybersecurity breaches, and potential loss of assets.
• Financial Performance Risks: The company has incurred significant losses and may require additional financing, which could be dilutive or costly, affecting its financial condition and stock price.

• Canton Strategic Holdings, Inc. is the first publicly traded company to leverage Canton Coin (CC) and support the Canton Network to advance institutional blockchain adoption and digitization of financial markets [S1].
• From 2022 through late 2025, the company primarily operated as a biotechnology company developing therapeutic candidates in inflammatory and immunologic conditions [S1].
• In November 2025, the company shifted its strategic focus to disciplined digital asset treasury management and investment in the Canton Network ecosystem [S1].
• The company operates as a Super Validator on the Canton Network and intends to run additional validator nodes to earn protocol-based validation rewards in CC and support network security and governance [S1].
• It plans to build, sponsor, or invest in applications and middleware that complement capital markets transactions on the Canton Network, focusing on projects built on or tightly integrated with the network [S1].
• The company collaborates with other Super Validators and ecosystem participants including financial institutions and technology providers to enhance network infrastructure and workflows [S1].
• It may access capital markets through offerings and an ATM program to deploy proceeds toward additional CC acquisitions and ecosystem investments [S1].
• Token management strategies include locking, lending, and options on CC holdings to generate yield and manage risk [S1].
• The company is an active participant and board member of the Canton Foundation, helping shape governance, tokenomics, and strategic roadmap [S1].
• The Canton Network is a public, permissionless blockchain designed for institutional privacy and interoperability, processing over $6 trillion in tokenized real-world assets [S1].
• CC is the native utility token used for transaction fees and rewards, with a declining issuance curve and a burn-and-mint equilibrium model to maintain sustainability [S1].
• The company holds substantially all CC tokens in custody with institutional-grade custodians under regulatory regimes designed to protect customer assets in insolvency events [S1].
• The company reported a net loss of $35.9 million for the year ended December 31, 2025, with basic and diluted EPS of -$1.12 [S1].
• As of December 31, 2025, the company had cash and equivalents of approximately $7.6 million and current assets of about $17.4 million, with current liabilities of approximately $3.3 million, resulting in a current ratio of 5.29 and a cash ratio of 2.32 [S1].
• The company’s pivot to a CC treasury strategy represents a fundamental change in risk profile, including potential loss of revenue streams from biotechnology operations and residual liabilities from prior activities [S1].
• The company faces regulatory risks related to crypto assets, including potential changes in laws, enforcement actions, and classification of CC as a security, which could materially impact its business and stock price [S1].
• CC holdings are subject to market volatility, liquidity constraints, custody risks, and cybersecurity challenges [S1].
• The company’s financial results and stock price may be materially affected by the price fluctuations of CC [S1].
• Recent business news includes Tharimmune’s appointment of Radkowski as COO and CEO Wendland as Chairman, approval for Tharimmune to run a Super Validator on the Canton Network, and executive appointments at Tharimmune [N1][N2][N3].